Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical cannabidiol/niacinamide serum plus doxycycline versus placebo serum plus doxycycline in moderate acne vulgaris
IRCT20260924071175N1Phase 3Recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cannabidiol, nicotinamide and doxycycline in acne vulgaris (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Change in inflammatory lesion count, Change in non-inflammatory lesion count and 5 more. Started Oct 2026; status: recruiting.
02
Drugs
cannabidiolnicotinamidedoxycycline
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on IRCT20260924071175N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260924071175N1.